It comes amid reports that the drugs maker is considering moving its listing from the UK to the US in what would be a hammer ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

AstraZeneca is reportedly considering moving its listing to the US. Here's why AZN's expected departure is alarming for the ...

Sky's James Sillars writes that a government, struggling for authority and prioritising economic growth, can not afford to ...

Reports are circulating that AstraZeneca shares could be moving off the London exchange with its CEO favouring a US market ...

AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...

AstraZeneca chief executive Sir Pascal Soriot is reportedly considering the move due to growing frustration with the UK's ...

(Reuters) -AstraZeneca chief executive Pascal Soriot is considering moving the company's stock market listing to the United ...

The government must urgently abolish stamp duty on shares and abolish new cash ISAs to prevent the London Stock Exchange losing it’s most valuable listing, Astrazeneca, says Michael Healy The UK stock ...

HSBC and Shell are the only two British companies in the top 100 of Forbes’ Global 2000, but its presence grows with 68 scattered throughout the list.

(Reuters) -AstraZeneca said on Tuesday that U.S. regulators have approved its precision drug Datroway to treat a type of lung ...